Blood, cerebrospinal fluid (CSF) and brain GCase activity levels have been shown to be lower in idiopathic PD as well as GBA-PD, suggesting that novel GBA targeted therapies may also be beneficial in idiopathic PD [126,127,128]. This evidence concerns the gene GBA1 and Parkinson disease.